BioCentury
ARTICLE | Company News

CV/NASH play Madrigal finds public path via Synta merger

April 15, 2016 12:08 AM UTC

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) and Madrigal Pharmaceuticals Inc. (Fort Washington, Pa.) will reverse-merge to create a company focused on non-alcoholic steatohepatitis (NASH), cardiovascular and metabolic diseases. The combined, publicly traded company will retain Madrigal's name.

This year, the merged company expects to start Phase II studies on lead compound MGL-3196 for NASH and heterozygous familial hypercholesterolemia (HeFH), as well as a smaller Phase IIa study in homozygous familial hypercholesterolemia. It expects data in early 2017 from the familial hypercholesterolemia studies, along with three-month top-line data and biomarker data from the NASH study. ...